Home pageCVM • NYSEAMERICAN
add
CEL-SCI Corp
0,73 $
After Hours:(1,80%)-0,013
0,71 $
Data e ora chiusura: 8 nov, 16:09:36 GMT-5 · USD · NYSEAMERICAN · Disclaimer
Chiusura precedente
0,71 $
Intervallo giornaliero
0,70 $ - 0,75 $
Intervallo annuale
0,68 $ - 3,23 $
Cap di mercato
44,75 Mln USD
Volume medio
300.101,00
Rapporto P/E
-
Dividendo/Prezzo
-
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
(USD) | giu 2024info | Variazione Y/Y |
---|---|---|
Entrate | — | — |
Spese di gestione | 1,97 Mln | -19,84% |
Utile netto | -7,52 Mln | 10,17% |
Margine di profitto netto | — | — |
Utili per azione | — | — |
EBITDA | -5,69 Mln | 20,98% |
Aliquota fiscale effettiva | — | — |
Stato patrimoniale
Totale attivo
Totale passivo
(USD) | giu 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 435.781,00 | -91,55% |
Totale attivo | 24,07 Mln | -25,53% |
Totale passivo | 15,60 Mln | -11,03% |
Patrimonio netto totale | 8,47 Mln | — |
Azioni in circolazione | 61,49 Mln | — |
Prezzo/valore contabile | 4,43 | — |
Redditività dell'attivo | -61,63% | — |
Rendimento sul capitale | -70,15% | — |
Flusso di cassa
Flusso di cassa netto
(USD) | giu 2024info | Variazione Y/Y |
---|---|---|
Utile netto | -7,52 Mln | 10,17% |
Liquidità di esercizio | -4,58 Mln | 19,19% |
Contanti da investimenti | -23.472,00 | 88,08% |
Contanti da finanziamenti | -322.303,00 | -133,87% |
Flusso di cassa netto | -4,92 Mln | -0,27% |
Flusso di cassa libero | -1,94 Mln | 32,46% |
Informazioni
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
Fondazione
mar 1983
Sito web
Dipendenti
43